Clinical Scorecard: Toxicity and Non-Relapse Mortality Associated with BCMA-Targeted T Cell Therapies in Multiple Myeloma: Insights from an FAERS Database Analysis
At a Glance
Category
Detail
Condition
Relapsed/Refractory Multiple Myeloma
Key Mechanisms
BCMA-directed T cell therapies including CAR T-cell therapies (ide-cel, cilta-cel) and bispecific antibodies (teclistamab) targeting B-cell maturation antigen
Target Population
Patients with relapsed/refractory multiple myeloma
Teclistamab showed the highest rates of life-threatening events (11.3%), hospitalizations (53.5%), and deaths (22.1%) among BCMA therapies analyzed.
Ide-cel had the highest reporting odds ratio (ROR) for cytokine release syndrome (CRS) and non-ICANS neurotoxicity; cilta-cel had higher ROR for infections; teclistamab had highest ROR for infections but lowest for CRS and neurotoxicity.
Non-relapse mortality (NRM) was lowest with ide-cel (OR 0.53), intermediate with cilta-cel (OR 0.99), and highest with teclistamab (OR 1.72), with infections predominating NRM in teclistamab cases.
Guideline-Based Recommendations
Diagnosis
Monitor for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, and infections in patients receiving BCMA-targeted therapies.
Management
Implement prompt recognition and management of CRS and neurotoxicity, especially in CAR T-cell therapies ide-cel and cilta-cel.
Vigilantly monitor and treat infections, particularly in patients receiving teclistamab due to higher infection risk.
Monitoring & Follow-up
Regular assessment for neurological symptoms including encephalopathy, tremor, aphasia, delirium, Parkinsonism, and cranial nerve palsies.
Close surveillance for infectious complications such as pneumonia, sepsis, COVID-19, Pneumocystis jirovecii pneumonia, and CMV reactivation.
Risks
Higher risk of CRS and neurotoxicity with CAR T-cell therapies (ide-cel, cilta-cel).
Increased infection-related morbidity and mortality with bispecific antibody teclistamab.
Potential for non-relapse mortality related to therapy-associated toxicities.
Patient & Prescribing Data
Patients with relapsed/refractory multiple myeloma treated with FDA-approved BCMA-directed immunotherapies (ide-cel, cilta-cel, teclistamab).
CAR T-cell therapies require adequate organ function and have longer vein-to-vein times; bispecific antibodies like teclistamab offer off-the-shelf availability but are associated with higher infection rates and non-relapse mortality.
Clinical Best Practices
Select therapy considering patient’s disease aggressiveness, organ function, and infection risk profile.
Prepare for and manage CRS and neurotoxicity proactively in CAR T-cell therapy recipients.
Implement infection prophylaxis and early intervention strategies, especially for patients on teclistamab.
Recognize unique neurotoxicities such as Bell’s palsy and Parkinsonism predominantly with cilta-cel.
Use FAERS and other pharmacovigilance data to inform risk-benefit discussions and post-marketing surveillance.
